|
1
|
Wang C, Horby PW, Hayden FG and Gao GF: A
novel coronavirus outbreak of global health concern. Lancet.
395:470–473. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Jiang F, Deng L, Zhang L, Cai Y, Cheung CW
and Xia Z: Review of the clinical characteristics of coronavirus
disease 2019 (COVID-19). J Gen Intern Med. 35:1545–1549.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma
CL, Li SB, Wang HY, Zhang S, Gao HN, et al: Clinical findings in a
group of patients infected with the 2019 novel coronavirus
(SARS-Cov-2) outside of Wuhan, China: Retrospective case series.
BMJ. 368(m606)2020.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
World Health Organization. Coronavirus
disease 2019 (COVID-19) Situation Report-51, (urihttps://www.who.intsimplehttps://www.who.int).
|
|
5
|
World Health Organization. Coronavirus
disease 2019 (COVID-19) Situation Report-96, (urihttps://www.who.intsimplehttps://www.who.int).
|
|
6
|
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He
JX, Liu L, Shan H, Lei CL, Hui DSC, et al: Clinical characteristics
of coronavirus disease 2019 in China. N Engl J Med. 382:1708–1720.
2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
General Office of National Health
Committee. Notice on the issuance of a program for the diagnosis
and treatment of novel coronavirus (2019-nCoV) infected pneumonia
(fourth trial version to sixth trial version). urihttp://www.nhc.gov.cn/jkj/new_index.htmlsimplehttp://www.nhc.gov.cn/jkj/new_index.html.
|
|
8
|
Badawi A and Ryoo SG: Prevalence of
comorbidities in the Middle East respiratory syndrome coronavirus
(MERS-CoV): A systematic review and meta-analysis. Int J Infect
Dis. 49:129–133. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chen N, Zhou M, Dong X, Qu J, Gong F, Han
Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in
Wuhan, China: A descriptive study. Lancet. 395:507–513.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan
A, Dai J, Sun Q, Zhao F, Qu J and Yan F: Clinical characteristics
and imaging manifestations of the 2019 novel coronavirus disease
(COVID-19): A multi-center study in Wenzhou city, Zhejiang, China.
J Infect. 80:388–393. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ding Q, Lu P, Fan Y, Xia Y and Liu M: The
clinical characteristics of pneumonia patients coinfected with 2019
novel coronavirus and influenza virus in Wuhan, China. J Med Virol:
March 20, 2020. 10.1002/jmv.25781, 2020.
|
|
12
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu
Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet.
395:497–506. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chinese Digestion Association, Chinese
Medical Doctor Association; Chinese Society of Hepatology, Chinese
Medical Association. The protocol for prevention, diagnosis and
treatment of liver injury in coronavirus disease 2019. Zhonghua Gan
Zang Bing Za Zhi. 28:217–221. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
14
|
Guan GW, Gao L, Wang JW, Wen XJ, Mao TH,
Peng SW, Zhang T, Chen XM and Lu FM: Exploring the mechanism of
liver enzyme abnormalities in patients with novel
coronavirus-infected pneumonia. Zhonghua Gan Zang Bing Za Zhi.
28:100–106. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
15
|
Shlipak MG, Mattes MD and Peralta CA:
Update on cystatin C: Incorporation into clinical practice. Am J
Kidney Dis. 62:595–603. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Menon V, Shlipak MG, Wang X, Coresh J,
Greene T, Stevens L, Kusek JW, Beck GJ, Collins AJ, Levey AS and
Sarnak MJ: Cystatin C as a risk factor for outcomes in chronic
kidney disease. Ann Intern Med. 147:19–27. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sarnak MJ, Katz R, Stehman-Breen CO, Fried
LF, Jenny NS, Psaty BM, Newman AB, Siscovick D and Shlipak MG:
Cardiovascular Health Study. Cystatin C concentration as a risk
factor for heart failure in older adults. Ann Intern Med.
142:497–505. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Shlipak MG, Sarnak MJ, Katz R, Fried LF,
Seliger SL, Newman AB, Siscovick DS and Stehman-Breen C: Cystatin C
and the risk of death and cardiovascular events among elderly
persons. N Engl J Med. 352:2049–2060. 2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Dolhnikoff M, Duarte-Neto AN, de Almeida
Monteiro RA, da Silva LFF, de Oliveira EP, Saldiva PHN, Mauad T and
Negri EM: Pathological evidence of pulmonary thrombotic phenomena
in severe COVID-19. J Thromb Haemost. 18:1517–1519. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhang W, Zhao Y, Zhang F, Wang Q, Li T,
Liu Z, Wang J, Qin Y, Zhang X, Yan X, et al: The use of
anti-inflammatory drugs in the treatment of people with severe
coronavirus disease 2019 (COVID-19): The Perspectives of clinical
immunologists from China. Clin Immunol. 214(108393)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Channappanavar R and Perlman S: Pathogenic
human coronavirus infections: Causes and consequences of cytokine
storm and immunopathology. Semin Immunopathol. 39:529–539.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chousterman BG, Swirski FK and Weber GF:
Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol.
39:517–528. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z,
Xiang J, Wang Y, Song B, Gu X, et al: Clinical course and risk
factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: A retrospective cohort study. Lancet. 395:1054–1062.
2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ruan Q, Yang K, Wang W, Jiang L and Song
J: Clinical predictors of mortality due to COVID-19 based on an
analysis of data of 150 patients from Wuhan, China. Intensive Care
Med. 46:846–848. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S,
Huang H, Zhang L, Zhou X, Du C, et al: Risk factors associated with
acute respiratory distress syndrome and death in patients with
coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern
Med. 180:934–943. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Radbel J, Narayanan N and Bhatt PJ: Use of
tocilizumab for COVID-19-induced cytokine release syndrome: A
cautionary case report. Chest. 158:e15–e19. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang S, Li L, Shen A, Chen Y and Qi Z:
Rational use of tocilizumab in the treatment of novel coronavirus
pneumonia. Clin Drug Investig. 40:511–518. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Xu Z, Shi L, Wang Y, Zhang J, Huang L,
Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al: Pathological findings
of COVID-19 associated with acute respiratory distress syndrome.
Lancet Respir Med. 8:420–422. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wei X, Zeng W, Su J, Wan H, Yu X, Cao X,
Tan W and Wang H: Hypolipidemia is associated with the severity of
COVID-19. J Clin Lipidol. 14:297–304. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Funderburg NT and Mehta NN: Lipid
abnormalities and inflammation in HIV inflection. Curr HIV/AIDS
Rep. 13:218–225. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zidar DA, Juchnowski S, Ferrari B, Clagett
B, Pilch-Cooper HA, Rose S, Rodriguez B, McComsey GA, Sieg SF,
Mehta NN, et al: Oxidized LDL levels are increased in HIV infection
and may drive monocyte activation. J Acquir Immune Defic Syndr.
69:154–160. 2015.PubMed/NCBI View Article : Google Scholar
|
